Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy ...

A new editorial paper titled "Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer" has been published in Oncotarget.

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC). A ...

Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...

FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...